{"nctId":"NCT03573297","briefTitle":"A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features","startDateStruct":{"date":"2018-06-15","type":"ACTUAL"},"conditions":["Bipolar I Disorder","Mania","Depression"],"count":901,"armGroups":[{"label":"Double-Blind Cariprazine 3.0 mg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Cariprazine"]},{"label":"Double-Blind Cariprazine 1.5 mg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Cariprazine"]},{"label":"Double-Blind Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Open Label Treatment","type":"EXPERIMENTAL","interventionNames":["Drug: Cariprazine"]}],"interventions":[{"name":"Cariprazine","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for bipolar I disorder, and at least one of the following two criteria:\n* Current episode manic, with or without mixed features, having a total Young Mania Rating Scale (YMRS) total score ≥ 20 and a score of at least 4 on 2 YMRS items (irritability, speech, content, or disruptive/aggressive behavior);\n* OR current episode depressive, with or without mixed features, having a Montgomery-Asberg Depression Rating Scale (MADRS) total score ≥ 23 and a score of at least 3 on 2 MADRS items (apparent sadness, reported sadness, inner tension or inability to feel).\n\nExclusion Criteria:\n\n* Four or more episodes of a mood disturbance within the 12 months before Visit 1;\n* Diagnosis of another psychiatric disorder other than bipolar disorder with the exception of specific phobias.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to First Relapse of Any Mood Episode During the Double-Blind Treatment Period","description":"Relapse was defined as the occurrence of any 1 of the following:\n\n* Young Mania Rating Score (YMRS) total score ≥ 17 (range 0-60; higher score indicates a worse outcome);\n* Montgomery Asberg Depression Rating Scale; (MADRS) total score ≥ 20 (range 0-60; higher score indicates more depressive symptoms);\n* Clinical Global Impression-Improvement scale (CGI-S) ≥ 4 (range from 1 \\[normal, not at all ill\\] to 7 \\[extremely ill\\]);\n* Initiation of additional psychiatric medication;\n* Psychiatric hospitalization;\n* Exacerbation of illness as judged by clinical impression of the Investigator.\n\nTime to first relapse (days) was calculated as the date of the first relapse - the date of randomization + 1. Participants who did not meet the relapse criteria were considered censored at the time of completion or discontinuation from the Double-Blind Treatment Period (DBTP) of the study. Percentiles (95% Confidence Intervals \\[CI\\]) are based on Kaplan-Meier estimates.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":896},"commonTop":["HEADACHE","AKATHISIA","INSOMNIA","WEIGHT INCREASED","NAUSEA"]}}}